Investigational drug · Phase 3
ASC40
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acne.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
6
Any phase or sponsor naming "ASC40"
First trial start
2024
Jan 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASC40", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acne
Approved drugs for the same conditions: Acne · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "ASC40" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne VulgarisPivotal-lookingCompleted
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT06192264 · 480 participants · Start Jan 23, 2024 · Primary completion May 19, 2025
Drug: ASC40 · For: Acne
Sites: Bengbu, China; Hefei, China; Wuhu, China · 41 sites in all
- A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne VulgarisPivotal-lookingCompleted
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT06248008 · 240 participants · Start Apr 18, 2024 · Primary completion Nov 12, 2025
Drug: ASC40 · For: Acne
Sites: Shanghai, China
- Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne VulgarisPivotal-lookingCompleted
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT05104125 · 180 participants · Start Jan 12, 2022 · Primary completion Apr 10, 2023
Drug: ASC40 25mg; ASC40 50mg and 2 more · For: Acne Vulgaris
Sites: Shanghai, China
- Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBMPivotal-lookingStatus unknown
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT05118776 · 136 participants · Start Jan 21, 2022 · Primary completion Jun 2025
Drug: ASC40 tablets; Placebo tablets and 1 more · For: Recurrent Glioblastoma
Sites: Beijing, China
Ascletis Pharmaceuticals Co., Ltd.Industry
NCT04843449 · 24 participants · Start Apr 4, 2021 · Primary completion May 6, 2021
Drug: ASC40; Itraconazole and 1 more · For: Healthy
Sites: Changsha, China
Mayo ClinicAcademic, hospital or other
NCT03179904 · 17 participants · Start Aug 3, 2017 · Primary completion Jul 30, 2024
Drug: Anastrozole; Denifanstat and 5 more · For: Advanced Breast Carcinoma; HER2-Positive Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8 and 2 more
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.